Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07204964 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
A Phase 2 study of Influenza, Human, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 960
- Enrollment target
- 17
- Study locations
NCT07204964: Recruiting Phase 2 study of Influenza, Human, sponsored by GlaxoSmithKline.
NCT07204964 is a Phase 2 study of Influenza, Human that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 960 participants, below the 16,170-participant average among 18 other Influenza, Human trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07204964, a Phase 2 study of Influenza, Human, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 960 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.
Conditions Studied
Interventions
- BIOLOGICAL Flu mRNA (Formulation B1)
- BIOLOGICAL Flu mRNA (Formulation B3)
- BIOLOGICAL Flu mRNA(Formulation A)
- COMBINATION_PRODUCT Comparator 1
- COMBINATION_PRODUCT Comparator 2
Study Locations (17)
Florida
- GSK Investigational Site - Hialeah
- GSK Investigational Site - Miami
- GSK Investigational Site - Pembroke Pines
California
- GSK Investigational Site - Canoga Park
- GSK Investigational Site - Walnut Creek
Nevada
- GSK Investigational Site - Carson City
- GSK Investigational Site - Las Vegas
Texas
- GSK Investigational Site - Austin
- GSK Investigational Site - Garland
Other
- GSK Investigational Site - Edegem
- GSK Investigational Site - Ghent
Alabama
- GSK Investigational Site - Guntersville
Georgia
- GSK Investigational Site - Stockbridge
North Carolina
- GSK Investigational Site - Greensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2026-09-17 |
| Phase | Phase 2 |
What NCT07204964 shows while recruiting
NCT07204964 is an interventional study that assigns participants to a tested intervention. The registered 960 participants enrollment target is mid-sized for trials with a published cap, below the 16,170-participant average among 18 other Influenza, Human trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 5 interventions - of which Flu mRNA (Formulation B1) is the first listed.
NCT07204964 lists 17 locations in 11 states (Florida, California, Nevada).
Frequently Asked Questions
What is clinical trial NCT07204964 about?
NCT07204964 is a clinical study titled "A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above". The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.
What is the current status of trial NCT07204964?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 960 participants. The study started on 2025-10-07. Estimated completion is 2026-09-17.
What conditions does trial NCT07204964 study?
This clinical trial studies the following conditions: Influenza, Human.
What interventions are being tested in trial NCT07204964?
The interventions under investigation include: Flu mRNA (Formulation B1) (BIOLOGICAL), Flu mRNA (Formulation B3) (BIOLOGICAL), Flu mRNA(Formulation A) (BIOLOGICAL), Comparator 1 (COMBINATION_PRODUCT), Comparator 2 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07204964?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07204964 being conducted?
This trial has 17 study locations across Alabama, California, Florida, Georgia, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza, Human
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07204964's enrollment target sits among peer trials
960 7th of 18 higher than 12 of 18 other Influenza, Human trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza, Human trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
COMPLETED · Phase 2
-
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
RECRUITING · Phase 4
-
Flu Infection at UPHS
RECRUITING
-
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI